ATE433323T1 - Verwendung von erythropoietin zur behandlung von primärer hämochromatosen - Google Patents

Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Info

Publication number
ATE433323T1
ATE433323T1 AT99920626T AT99920626T ATE433323T1 AT E433323 T1 ATE433323 T1 AT E433323T1 AT 99920626 T AT99920626 T AT 99920626T AT 99920626 T AT99920626 T AT 99920626T AT E433323 T1 ATE433323 T1 AT E433323T1
Authority
AT
Austria
Prior art keywords
erythropoietin
treatment
primary hemochromatosis
hemochromatosis
primary
Prior art date
Application number
AT99920626T
Other languages
English (en)
Inventor
Rene Gottschalk
Paul Lehmann
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998116035 external-priority patent/DE19816035A1/de
Priority claimed from EP98250222A external-priority patent/EP0965349A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of ATE433323T1 publication Critical patent/ATE433323T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99920626T 1998-04-09 1999-04-09 Verwendung von erythropoietin zur behandlung von primärer hämochromatosen ATE433323T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998116035 DE19816035A1 (de) 1998-04-09 1998-04-09 Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
EP98250222A EP0965349A1 (de) 1998-06-18 1998-06-18 Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
PCT/EP1999/002422 WO1999052542A1 (en) 1998-04-09 1999-04-09 Use of erythropoietin for the treatment of haemochromatoses

Publications (1)

Publication Number Publication Date
ATE433323T1 true ATE433323T1 (de) 2009-06-15

Family

ID=26045400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920626T ATE433323T1 (de) 1998-04-09 1999-04-09 Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Country Status (10)

Country Link
US (1) US6676947B1 (de)
EP (1) EP1085900B1 (de)
JP (1) JP3930250B2 (de)
AR (1) AR019025A1 (de)
AT (1) ATE433323T1 (de)
AU (1) AU3814599A (de)
DE (1) DE69940971D1 (de)
DK (1) DK1085900T3 (de)
ES (1) ES2326501T3 (de)
WO (1) WO1999052542A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
KR100701422B1 (ko) * 2004-07-29 2007-03-30 주식회사 하이닉스반도체 케미컬 어택을 방지할 수 있는 반도체소자 및 그 제조 방법
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
EP2316334A1 (de) 2009-10-22 2011-05-04 Fresenius Medical Care Deutschland GmbH Verfahren zur Beurteilung des Flüssigkeitszustands und/oder der Empfindlichkeit für eine Flüssigkeitsentfernung eines Patienten, Steuerung und Vorrichtungen
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
AU723740B2 (en) * 1995-06-06 2000-09-07 Howmedica Inc. Biocompatible hydroxyapatite formulations and uses therefor
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
FI964138L (fi) 1996-10-15 1998-04-16 Nokia Telecommunications Oy Kanavanvarausmenetelmä ja radiojärjestelmä

Also Published As

Publication number Publication date
AR019025A1 (es) 2001-12-26
ES2326501T3 (es) 2009-10-13
JP2002511418A (ja) 2002-04-16
US6676947B1 (en) 2004-01-13
AU3814599A (en) 1999-11-01
DE69940971D1 (de) 2009-07-23
EP1085900B1 (de) 2009-06-10
DK1085900T3 (da) 2009-08-10
WO1999052542A1 (en) 1999-10-21
EP1085900A1 (de) 2001-03-28
JP3930250B2 (ja) 2007-06-13

Similar Documents

Publication Publication Date Title
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE59905858D1 (de) Verwendung von pit-emulsionen
DE69903655D1 (de) Verwendung von menthyl-2-pyrrolidon-5-carboxylat zur insektenabwehr
DE69720463T2 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE300597T1 (de) Behandlung von geweben
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1085900

Country of ref document: EP